Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 4/20 | 0.62 |
| ▸ | PTGES | O14684 | 2/20 | 0.62 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 0.59 |
| ▸ | PRKCG | P05129 | 1/20 | 0.55 |
| ▸ | NT5E | P21589 | 5/20 | 0.54 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.54 |
| ▸ | CETP | P11597 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3787381 | 1.00 | CA9 (0.62) | CA9PTGESSLC10A1PRKCGNT5E | |
| SCHEMBL3792174 | 0.90 | PTPN1 (0.64) | PTGESNT5EPTPN1 | |
| SCHEMBL3792177 | 0.90 | PTPN1 (0.64) | PTGESNT5EPTPN1 | |
| SCHEMBL6119253 | 0.87 | CA9 (0.67) | CA9PTGESSLC10A1PRKCGNT5E | |
| SCHEMBL6119298 | 0.84 | SLC10A1 (0.65) | CA9PTGESSLC10A1PRKCGNT5E | |
| SCHEMBL6112658 | 0.83 | CA9 (0.62) | CA9PTGESSLC10A1PRKCGNT5E | |
| SCHEMBL6112790 | 0.82 | PTPN1 (0.51) | SLC10A1NT5EPTPN1 | |
| SCHEMBL6112792 | 0.82 | PTPN1 (0.51) | SLC10A1NT5EPTPN1 | |
| SCHEMBL10214430 | 0.82 | PTGES (0.83) | CA9PTGESSLC10A1NT5EPRKCD | |
| SCHEMBL214200 | 0.82 | PTGES (0.83) | CA9PTGESSLC10A1NT5EPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969395-B2 | Triterpenoid derivatives useful as antiproliferative agents | UNIVERSIDADE DE COIMBRA (PT) | 2015-03-03 | — | — | US | disclosed |
| US-20120129901-A1 | TRITERPENOID DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | UNIVERSIDADE DE COIMBRA (PT) | 2012-05-24 | — | — | US | disclosed |
| WO-2010134830-A1 | TRITERPENOID DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | UNIVERSIDADE DE COIMBRA (PT) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129901-A1 | TRITERPENOID DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | ALPI, LSS, CYP46A1 | CA9 362/4885PTGES 1262/4885SLC10A1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.